Anti-3[18F] FACBC for the Detection and Staging of Recurrent Prostate Carcinoma

Prostate cancer is the most common non-cutaneous malignancy in men, comprising 33% of newly diagnosed cancers in the US in 2005. Approximately one-third of patients after potentially curative therapy will develop a biochemical recurrence manifested by a rising post-treatment PSA. Recurrence can occur within the prostate bed or at locoregional lymph nodes or distant sites and the absolute PSA value itself cannot make this differentiation. Yet this differentiation is important in management decisions and in recommending subsequent salvage therapy. The most appropriate therapeutic intervention for asymptomatic patients with evidence of biochemical failure remains undefined because of lack of appropriate testing modalities to distinguish between local, loco-regional, or distant prostate cancer. The purpose of this prospective clinical trial is to evaluate anti-[18F] FACBC’s usefulness in improving patient care resulting from detection of recurrent disease and discrimination of prostatic from extraprostatic recurrence. In addition, by developing preliminary data to elucidate the mechanism of specific LAT transportation and signaling pathways, this study could encourage the potential use of anti-[18F] FACBC in future studies as a measure of responsiveness to drugs that inhibit specific signaling transduction pathways.                               

Funding Agency: National Institutes of Health
PI: David M Schuster, MD
Grant Type: R01 CA 129356
Funding Period: 09/21/07-07/31/13

For further information about this study: